Assignee

MINERVA NEUROSCIENCES INC

US·9 granted patents·23 pending applications·56 citations·filing 2014–2025

Technology mixA61K30 A61P29 C07D21 C07B7 A01N6 H04L3

Top patents by PatentIndex Score

32 records

0194US10799493B2Compositions and methods for treating schizophreniaMINERVA NEUROSCIENCES INC·Filed 2019·Granted Oct 13, 2020·7 cites·20 claims
0294US9458130B2Compositions and methods for treating schizophreniaMINERVA NEUROSCIENCES INC·Filed 2015·Granted Oct 4, 2016·20 cites·14 claims
0393US9730920B2Compositions and methods for treating schizophreniaMINERVA NEUROSCIENCES INC·Filed 2016·Granted Aug 15, 2017·12 cites·20 claims
0492US10258614B2Compositions and methods for treating schizophreniaMINERVA NEUROSCIENCES INC·Filed 2017·Granted Apr 16, 2019·10 cites·34 claims
0589US11083723B2Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotectionMINERVA NEUROSCIENCES INC·Filed 2019·Granted Aug 10, 2021·3 cites·20 claims
0688US2025195494A1Compositions and methods for treating schizophreniaMINERVA NEUROSCIENCES INC·Filed 2024·Application pending·0 cites
0787US12048768B2Gastro-resistant controlled release oral dosage formsMINERVA NEUROSCIENCES INC·Filed 2022·Granted Jul 30, 2024·1 cites·21 claims
0886US11464744B2Gastro-resistant controlled release oral dosage formsMINERVA NEUROSCIENCES INC·Filed 2018·Granted Oct 11, 2022·3 cites·12 claims
0983US2023201184A1Compositions and methods for treating schizophreniaMINERVA NEUROSCIENCES INC·Filed 2023·Application pending·0 cites
1076US2025009665A1Gastro-resistant controlled release oral dosage formsMINERVA NEUROSCIENCES INC·Filed 2024·Application pending·0 cites
1175US2023248714A1(2s)-1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy] propan-2-ol or its metabolite for treating anxiety disordersMINERVA NEUROSCIENCES INC·Filed 2023·Application pending·0 cites
1273US2025109127A1Methods of use of phenoxypropylamine compounds to treat depressionMINERVA NEUROSCIENCES INC·Filed 2024·Application pending·0 cites
1372US2025179044A1Methods of use of cyclic amide derivatives to treat schizophreniaMINERVA NEUROSCIENCES INC·Filed 2024·Application pending·0 cites
1471US2021228561A1Compositions and methods for treating schizophreniaMINERVA NEUROSCIENCES INC·Filed 2020·Application pending·0 cites
1571US2024376068A1Sigma ligand compounds and uses thereofMINERVA NEUROSCIENCES INC·Filed 2024·Application pending·0 cites
1670US2024016790A1Methods of using a phenoxypropylamine compound to treat painMINERVA NEUROSCIENCES INC·Filed 2023·Application pending·0 cites
1769US11766430B2Methods of using a phenoxypropylamine compound to treat painMINERVA NEUROSCIENCES INC·Filed 2019·Granted Sep 26, 2023·0 cites·18 claims
1867US2023190726A1Compositions and methods for treating negative symptoms in non-schizophrenic patientsMINERVA NEUROSCIENCES INC·Filed 2022·Application pending·0 cites
1967US2022096455A1Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotectionMINERVA NEUROSCIENCES INC·Filed 2021·Application pending·0 cites
2066US2025235443A1Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotectionMINERVA NEUROSCIENCES INC·Filed 2025·Application pending·0 cites
2165US2022274951A1Methods of use of cyclic amide derivatives to treat schizophreniaMINERVA NEUROSCIENCES INC·Filed 2022·Application pending·0 cites
2265US2025228837A1(2s)-1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy] propan-2-ol or its metabolite for treating anxiety disordersMINERVA NEUROSCIENCES INC·Filed 2025·Application pending·0 cites
2363US2025228838A1Methods of use of cyclic amide derivatives to treat sigma receptor mediated disordersMINERVA NEUROSCIENCES INC·Filed 2025·Application pending·0 cites
2462US12006300B2Sigma ligand compounds and uses thereofMINERVA NEUROSCIENCES INC·Filed 2021·Granted Jun 11, 2024·0 cites·41 claims
2561US2021106573A1Methods of use of cyclic amide derivatives to treat sigma receptor mediated disordersMINERVA NEUROSCIENCES INC·Filed 2020·Application pending·0 cites
2660US2023255953A1Use of roluperidone in preventing relapse in schizophrenia patientsMINERVA NEUROSCIENCES INC·Filed 2023·Application pending·0 cites
2755US2019216793A1Compositions and methods for treating negative symptoms in non-schizophrenic patientsMINERVA NEUROSCIENCES INC·Filed 2017·Application pending·0 cites
2854US2020223838A1Methods of use of phenoxypropylamine compounds to treat depressionMINERVA NEUROSCIENCES INC·Filed 2020·Application pending·0 cites
2951US2018155318A1Methods of use of cyclic amide derivatives to treat schizophreniaMINERVA NEUROSCIENCES INC·Filed 2017·Application pending·0 cites
3051US2019183874A1(2s)-1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy] propan-2-ol or its metabolite for treating anxiety disordersMINERVA NEUROSCIENCES INC·Filed 2017·Application pending·0 cites
3149US2014206722A1Methods of use of phenoxypropylamine compounds to treat depressionMINERVA NEUROSCIENCES INC·Filed 2014·Application pending·0 cites
3246US2016354357A1Methods of use of cyclic amide derivatives to treat sigma receptor mediated disordersMINERVA NEUROSCIENCES INC·Filed 2016·Application pending·0 cites

Join the waitlist — get patent alerts

Get an alert when MINERVA NEUROSCIENCES INC files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →